Features | Partner Sites | Information | LinkXpress
Sign In
Demo Company

Biomarkers Market Expected to Flourish at CAGR 18.5% to 2018

By BiotechDaily International staff writers
Posted on 15 Oct 2013
The global biomarkers market demonstrates high growth possibilities and accounts for USD 17.5 billion in 2013. It is expected to grow at a compound annual growth rate (CAGR) of 18.5% from 2013 to 2018, to reach USD 40.8 billion by 2018, according to a recent market report.

A biomarker is an identifiable and measurable characteristic, which identifies the severity and/or occurrence of a specific disease. It has major applications in the discovery and development of novel therapeutic drugs.

Recent developments in discovery technologies, high demand from the indications of various diseases, increasing collaborations to boost biomarker research activities, increase in government and private sector investments and funds for biomarker discovery, US Food and Drug Administration (FDA) support for biomarker development, and increasing utility of biomarkers in patient stratification and drug development process are the key drivers slated to fuel the growth of this market. However, a few essential factors such as the high capital investment and low benefit-cost ratio, cumbersome biomarker validation procedure, and difficulty in sample collection and its storage are expected to hamper the growth of this market, according to internet market research company RnRMarketResearch.com (Dallas, TX, USA).

The global market has been segmented into discovery technologies, services, applications, and disease indications. The biomarker discovery technology market has been further segmented into ‘omics technology, imaging technology, and bioinformatics. The ‘omics technology sector accounts for the largest share in this market, chiefly due to the increase in adoption of proteomics and genomics technologies worldwide.

Drug discovery and development segment holds the largest share of biomarker applications market. This is attributed to the potential of biomarkers to reduce the time span of clinical trials, which ultimately decreases the overall cost of the entire drug discovery and development process.

The global biomarkers market, on the basis of type of disease, is additionally classified as oncology, cardiology, neurology, and other diseases (renal disorders, HIV, diabetes, arthritis, and tuberculosis). Oncology biomarkers market accounts for the major share of the biomarker disease indication market, and furthermore, this market is forecast to grow at the highest growth rate in the next five years. Increasing need for the early diagnosis of tumor cells is the major factor stimulating the growth of oncology market. Oncology biomarkers enhance the screening and early detection of cancer as well as facilitate the high-speed, noninvasive cancer diagnosis procedure, according to RnRMarketResearch dot com analysts.

The key players in this market are Roche Diagnostics Limited (Switzerland), Johnson & Johnson (United States), GlaxoSmithKline, Plc. (United Kingdom), Siemens Healthcare (Germany), Abbott Laboratories, Inc. (United States), GE Healthcare (United Kingdom), Affymetrix, Inc. (United States), Thermo Fisher Scientific, Inc. (United States), Epigenomics, AG (Germany), Eisai Co., Ltd. (Japan), Bio-Rad Laboratories, Inc. (United States), Eli Lilly and Company (United States), Merck & Co. (United States), Genomic Health, Inc. (United States), and Agilent Technologies, Inc. (United States).

RnRMarketResearch.com is an online database of market research reports that provide analysis of over 5,000 market segments. The library has syndicated reports by market research publishers worldwide and also offer customized market research reports for multiple industries.

Related Links:




view channel
Image: A new catalyst that improved the sensitivity of the standard PSA ELISA test by about 110-fold was made of palladium nanocubes coated with iridium (Photo courtesy of Dr. Xiaohu Xia, Michigan Technological University).

Peroxidase Mimic Outperforms Natural Horseradish Peroxidase in ELISA Test

A test-of-concept study demonstrated that a synthetic catalyst that mimics the action of horseradish peroxidase (HRP) could increase the sensitivity of a colorimetric enzyme-linked immunosorbent assay... Read more

Drug Discovery

view channel
Image: Endoscopic image of a bowel section known as the sigmoid colon afflicted with ulcerative colitis. The internal surface of the colon is blotchy and broken in places (Photo courtesy of Wikimedia Commons).

Orally Delivered Curcumin-Loaded Microparticles Effectively Treat Mouse Model of Ulcerative Colitis

Microparticles (MPs) loaded with the efficient anti-inflammatory agent curcumin were found to effectively treat a mouse model of ulcerative colitis. Ulcerative colitis is a chronic relapsing disease... Read more

Lab Technologies

view channel

New Genomic Research Kit Simplifies Exome Studies

An exciting new tool is now available for biotech researchers working in the field of genomic analysis. The human exome is critical to our genetic make-up and is generally accepted as having the greatest influence on how the genetic blueprint is utilized. The exome is defined as all coding exons in the genome and is... Read more


17 Oct 2015 - 21 Oct 2015
25 Oct 2015 - 29 Oct 2015
16 Nov 2015 - 19 Nov 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.